RESUMO
Nocturia is a pathologic condition that significantly affects the quality of sleep. The aetiology of nocturia is multifactorial, and the evidence available on its management remains limited. Besides behavioural measures, validated pharmaceutical treatment options exist but are, however, associated with marked side effects. Prospective clinical studies with tablets prepared from the leaf press juice of the plant Bryophyllum pinnatum revealed a tendency towards reduction of micturition in patients with overactive bladder (OAB) and several improvements in sleep quality. These observations are in part supported by in vitro and in vivo data. In the present study, we investigated the effectiveness of Bryophyllum 50% chewable tablets in the treatment of nocturia and associated sleep disorders. Altogether, 49 women with idiopathic OAB and nocturia of ≥2 voids/night were treated with Bryophyllum 50% tablets for 3 weeks (350 mg chewable tablets, dosage 0-0-2-2 oral tablets; WELEDA AG, Arlesheim, Switzerland). Nocturia, voiding volumes at night (ml), quality of life, sleep quality, and daily sleepiness were assessed before and after treatment with a 3-day micturition diary, the International Consultation on Incontinence evaluating overactive bladder and related impact on quality of life (QoL) [ICIQ-OAB], the Pittsburgh Sleep Quality Index (PSQI), and the Epworth Sleepiness Scale (ESS), respectively. The age of the study population was 68.5 ± 11.6 y. After treatment, nocturia diminished from 3.2 ± 1.4 to 2.3 ± 1.3 (P < 0.001) and the PSQI score decreased from 7.7 ± 3.7 to 6.6 ± 3.4 (P=0.004). Urgency, the ICIQ score, and the ESS lowered significantly, and the micturition volume showed a tendency to increase. No serious adverse drug reactions were reported, and compliance was good. The results show a beneficial effect on the nocturnal voids and sleep quality of women with OAB. Bryophyllum 50% tablets can be regarded as a well-tolerated alternative in the treatment of nocturia and broaden the repertoire of standard management.
RESUMO
AIM: Postpartum haemorrhage (PPH) is one of the leading causes of maternal morbidity and mortality. Studies have reported an increase in incidence of postpartum haemorrhage in recent years. Our goal was to investigate changes in the incidence of postpartum haemorrhage (PPH) and its risk factors in Switzerland from 1993 to 2014. METHODS: This population-based retrospective cohort study used data from the national Swiss Hospital in-patient database for obstetric and gynaecological hospital admissions - "Arbeitsgemeinschaft Schweizer Frauenkliniken" (ASF Statistik). All patients with deliveries between January 1993 and December 2014 were included. We used the database codes to identify patients with PPH, maternal factors, pregnancy-related and delivery-related factors. Significant changes in temporal trends were determined using Mantel-Haenszel test for trend. Multivariable logistic regression analyses were conducted to assess PPH and risk factors. RESULTS: Births complicated by PPH in Switzerland increased from 2.5% in 1993 to 4.5% in 2014 (p <0.001), paralleled by an increase in uterine atony. Failure to progress during the second stage of labour (odds ratio [OR] 1.5, 95% confidence interval [CI] 1.5-1.6), oxytocin augmentation (OR 1.2, 95% CI 1.2-1.3), vacuum extraction (OR 1.1, 95% CI 1.1-1.2), and especially abnormally invasive placenta (OR 10.4, 95% CI 9.5-11.5) and placenta praevia (OR 4.9, 95% CI 432-5.6) were factors with the highest risk for postpartum haemorrhage. CONCLUSIONS: Postpartum haemorrhage is a relatively common and potentially dangerous obstetric complication with increasing incidence over the last two decades in Switzerland. Its increase over time has been paralleled by an increase in uterine atony.